ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Unveils R&D Strategy Shift

by Lisa M. Jarvis
January 6, 2014 | APPEARED IN VOLUME 92, ISSUE 1

Merck & Co. is beginning to pull back the curtain on its R&D strategy under Roger Perlmutter, who left Amgen last year to head Merck’s research operations. The drug company will lessen its traditional focus on in-house research and increasingly look for discoveries made outside its own labs. As such, Merck will establish innovation hubs in Boston, the San Francisco Bay Area, London, and Shanghai as a means of accessing cutting-edge science from academic experts and biotech firms. The news of Merck’s shift was first reported in the Wall Street Journal; Merck confirmed the story’s details but declined to offer further comment.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment